|Bid||0.0000 x 4000|
|Ask||4.6900 x 29200|
|Day's Range||4.3000 - 4.8700|
|52 Week Range||1.9700 - 12.4900|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.78|
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources. Six companies have disclosed in regulatory filings that they have received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York, according to the report. Teva Pharmaceutical Industries Ltd. is down 8%, Mallinckrodt 5%, Amneal Pharmaceuticals Inc. 10%, and Johnson & Johnson 1%. Shares of cited wholesale drug distributors also declined, AmerisourceBergen by 3% and McKesson by 5%. In addition, shares of companies facing opioid litigation but not cited in the Journal story also dropped, with Endo International down 9% and Cardinal Health 4%. In recent weeks, the stocks of these companies have rallied as investors took the view that the possibility of global settlement that would resolve all pending and future litigation was a positive.
Shares of generic drugmakers jumped Monday as speculation mounts about a series of legal settlements potentially nearing a resolution.
Shares of generic drugmakers are up in morning trading, with Mallinckrodt leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd. is up 5%, Mylan up 4% and Endo International 4%. Bloomberg reported Monday morning that sources have said Teva and other drugmakers, including Sun Pharmaceutical Industries, are in talks with the Department of Justice to resolve allegations of price-fixing in the generic drug market. Separately, SVB Leerink analysts said this week that if plans for Endo, Mallinckrodt and Teva to enter into a "global opioid settlement framework" with state attorneys general go through, likely in the fourth quarter of 2019 or the first quarter of 2020, it would be a positive for those companies. "We could also see read-through for other opioid-levered names like Endo and Mallinckrodt," the analysts wrote in a Nov. 24 note.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise Continue reading...
Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
It is doubtless a positive to see that the Endo International plc (NASDAQ:ENDP) share price has gained some 78% in the...
Endo International said this week that Paul Campanelli, president and CEO, will step down when a successor is named. A successor has not yet been appointed. Campanelli, who took over the top job at Endo in 2016, has been named board chairman. "We're going to need somebody that can look across multiple segments and also medical aesthetics," Campanelli told investors on Tuesday. Endo's stock is down $43.15 year-to-date, while the S&P 500 has climbed about 23%.
NEW YORK, NY / ACCESSWIRE / November 5, 2019 / Endo International Plc (NASDAQ: ENDP ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on November 5, 2019 at 7:30 ...
Endo (ENDP) delivered earnings and revenue surprises of 13.21% and 3.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?